Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control
- 1 March 2011
- journal article
- Published by Springer Nature in Diabetology International
- Vol. 2 (1) , 32-44
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes, Obesity and Metabolism, 2007
- Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drugDiabetes, Obesity and Metabolism, 2007
- Contemporary Analysis of Secondary Failure of Successful Sulfonylurea TherapyEndocrine Practice, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2006
- The status of diabetes control and antidiabetic drug therapy in Japan—A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1)Diabetes Research and Clinical Practice, 2006
- The place of sulfonylureas in the therapy for type 2 diabetes mellitusMetabolism, 2006
- The biology of incretin hormonesCell Metabolism, 2006
- Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetesDiabetes Research and Clinical Practice, 2004
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985